JMP Securities analyst Donald Ellis lowered his price target on Evolus to $30 after its Q2 earnings miss and to reflect the updated share count for the stock in his valuation model. The analyst is keeping his Outperform rating however, noting that the company's launch of JEUVEAU on May 15 has exceeded expectations on several metrics, including "physician practices joining the JET trial" and patient satisfaction. Ellis maintains his expectation for JEUVEAU to achieve the management's target of a #2 position in the U.S. aesthetic toxin market.

The company states: "Evolus announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau(R) (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients. The "extra-strength" glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau(R) Extra-Strength 40U and two active controls, BOTOX(R) 20U and Jeuveau(R) 20U. Efficacy results demonstrated 26 weeks, or 6 months duration across the multiple metrics presented, including the time it took for patients to return to their baseline GLS score after their treatment, the duration of effect for a patient with at least a one-point GLS improvement, and the time it took a patient to return to their baseline using the Global Aesthetic Improvement Scale. The safety profile was similar across all three arms and overall, 88.9% of adverse events were rated as mild and no serious adverse events were identified."